MYCOF News and Press, New Age Brands From 04/12/22

In 2021, Mydecine made significant progress in creating and commercializing new treatments for mental health and addiction disorders It also made a noteworthy shift in focus to reducing expenses and increasing efficiencies for continued clinical trials and the expansion of its IP portfo...

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. A recent article discusses the company’s efforts to lead the charge toward developing novel psychedelic an...

Mydecine was founded in 2020 as a response to the lack of innovation addressing mental health treatment and the therapeutic possibilities represented by psychedelic compounds and other novel molecules The world is experiencing a shortage of mental health resources, while faced with an i...

New research has found that the experiences of people who talked about and reported nonsuicidal self-injury on Reddit are similar to individuals who have been diagnosed with substance use disorder. Individuals who posted on a self-injury forum titled r/self-harm in 2010–2019 cited...

A new study has looked into how therapeutic psychedelic administration combined with the calm properties of nature-based settings has the capacity to improve an individual’s mental well-being as well as bolster their relationship with nature. The study was conducted by a team of res...

Mydecine Innovations Group press release (OTCPK:MYCOF): FY GAAP EPS of -C$0.12. The company had C$1.5M in cash and cash equivalents as of December 31, 2021. For further details see: Mydecine Innovations Group GAAP EPS of -C$0.12

MYCO-001 Smoking Cessation Clinical Trial Moves Forward Following Conditional IRB Approval Company Advances IP Portfolio With New Patent Applications Covering Novel Molecule Families DENVER, March 31, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MY...

Mydecine Innovations Group Announces Closing of First Tranche Under Share Subscription Agreement Canada NewsWire DENVER , March 31, 2022 /CNW/ - Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is...

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – March 30, 2022 –  Depression and anxiety affect millions around the world and the venom of a toad is the latest  psychedelic compound being used as an alternative treat...

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) , a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has continually taken steps toward fulfilling its mission to become a trusted source of safe and effective medication-ba...